Nipro Pharma Corporation Sustainability Profile
Nipro Pharma Corporation, a leading player in the pharmaceutical industry, is headquartered in Japan and operates extensively across Asia, Europe, and the Americas. Founded in 1954, the company has established itself as a key provider of high-quality medical products, particularly in the fields of dialysis, infusion therapy, and injectable pharmaceuticals. Nipro's commitment to innovation is evident in its diverse range of core products, which include advanced medical devices and pharmaceutical formulations designed to enhance patient care. The company is recognised for its rigorous quality standards and has achieved significant milestones, including numerous certifications and awards that underscore its market position. With a focus on research and development, Nipro Pharma continues to drive advancements in healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Nipro Pharma Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nipro Pharma Corporation's score of 27 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nipro Pharma Corporation's reported carbon emissions
Nipro Pharma Corporation, headquartered in Japan, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Nipro Corporation, which may influence its climate commitments and reporting practices. While Nipro Pharma Corporation has not established specific reduction targets or initiatives, it is important to note that emissions data may be inherited from its parent company, Nipro Corporation. This relationship suggests that any climate commitments or performance metrics may align with broader corporate strategies. Nipro Pharma Corporation's climate commitments are not explicitly detailed, and there are no reported initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The lack of specific emissions data and reduction targets highlights a potential area for improvement in transparency and accountability regarding their environmental impact. In summary, Nipro Pharma Corporation's current climate strategy appears to be in development, with no specific emissions data or reduction targets available at this time. The company may benefit from aligning its efforts with the sustainability initiatives of its parent organization, Nipro Corporation, to enhance its climate commitments and reporting.
How Carbon Intensive is Nipro Pharma Corporation's Industry?
How Carbon Intensive is Nipro Pharma Corporation's Location?
Nipro Pharma Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nipro Pharma Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
